Clinical trials: Psychotic Disorder
Psychotic Disorders
Facilitating Engagement in Evidence-Based Treatment for Early Psychosis
The purpose of this mixed methods study is to evaluate a peer-delivered decision support intervention with emerging adults newly enrolled in an early intervention program, also known as coordinated specialty care (CSC).
- Trial name
- NCT04532034
- Testing
- Peer-Delivered Decision Support Intervention
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Temple University
Schizophrenia and Disorders With Psychotic Features
One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist…
- Trial name
- NCT00748566
- Testing
- Ziprasidone HCL (oral)
- Where
- 32 sites in Canada
- Volunteers
- 172 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Cognition
Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic
This is a study of the effects of tDCS on smoking, craving for cigarettes, cognition, and psychiatric symptoms in schizophrenic patients who are current smokers or have a history of regular cigarette smoking.
- Conditions
- Schizophrenia, Cognition, Cigarette Smoking
- Trial name
- TDCSSCHIZ (NCT02128919)
- Testing
- tDCS
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia, Schizoaffective Disorder
Effect of Single Dose Intranasal Insulin On Cognitive Function
The purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffective disorders.
- Trial name
- NCT00646581
- Testing
- Insulin (Humulin)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Metabolic Evaluation, Cardiac Complications
Metabolic and Clinical Effect of Alpha-lipoic Acid Administration in Schizophrenic Subjects
The therapeutic use of ALA in schizophrenia has recently been investigated in human populations. A case series explored the effiacy of ALA as a novel agent to treat antipsychotic-induced obesity, at a dose of 1200 mg/d (range…
- Trial name
- NCT06787781
- Testing
- Alpha Lipoic Acid
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- University of Messina
Schizophrenia
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due…
- Trial name
- i-FANS (NCT01207414)
- Testing
- iloperidone
- Where
- 59 sites in United States
- Volunteers
- 501 people
- Sponsor
- Novartis
Parkinson's Disease Psychosis
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00658567
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 50 sites in United States, Austria and 7 more
- Volunteers
- 123 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits
The primary objective of this study is to evaluate if adjunctive armodafinil treatment can improve the cognitive deficits in patients with schizophrenia
- Trial name
- NCT00487942
- Testing
- armodafinil
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cephalon
Schizophrenia
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia
To determine whether a standardized extract of Withania somnifera will reduce psychopathology scores (PANSS total score) in persons with schizophrenia.
- Trial name
- NCT03437668
- Testing
- WSE
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Chengappa, K.N. Roy, MD
Organic Brain Syndrome, Nonpsychotic, Neurocognitive Disorders
Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome
The investigators have designed an innovative proof-of-concept trial designed to provide data as to whether the treatment/rehabilitation efficacy and functional outcome of patients with organic brain syndrome are improved with…
- Conditions
- Organic Brain Syndrome, Nonpsychotic, Neurocognitive Disorders, Mental Disorder, Organic, Delirium, Dementia, Amnestic, Cognitive Disorders
- Trial name
- NCT02957123
- Testing
- Intranasal auto-M2-BFs
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Russian Academy of Medical Sciences
Bipolar Disorder
Aripiprazole in Children and Adolescents With Bipolar I Disorder
The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.
- Trial name
- NCT00110461
- Testing
- Aripiprazole
- Where
- 53 sites in United States
- Volunteers
- 296 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Improving Cognition in Schizophrenia Using tDCS
This study will examine the benefits of transcranial direct current stimulation (tDCS), a new tool that is being developed as a safe and non-invasive neurostimulation method, for improving neurocognitive and social cognitive…
- Trial name
- ICDC (NCT02539797)
- Testing
- tDCS
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of California, Los Angeles
Schizophrenia
Patient-Centered Medication Adherence Intervention for Schizophrenia
Efficacious antipsychotic medication treatments for schizophrenia are available; however , antipsychotic regimens frequently do not achieve their potential because of poor medication adherence.
- Trial name
- AMAIS (NCT00144027)
- Testing
- Antipsychotic medication adherence intervention
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia
The purpose of this study is to assess the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and safety of paliperidone palmitate in participants with schizophrenia (psychiatric…
- Trial name
- NCT01606254
- Testing
- Paliperidone palmitate
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia, Schizoaffective Disorder
Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes
The primary goal of this study is to examine the triglyceride/high-density lipoprotein (TG/HDL) ratio and the ischemic EKG changes in patients with schizophrenia, schizoaffective disorder or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00288353
- Testing
- aripiprazole (Abilify), ziprasidone (Geodon)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Northwestern University
Schizophrenia
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo.
- Trial name
- NCT04072354
- Testing
- SEP-363856 50mg, SEP-363856 75mg
- Where
- 53 sites in United States, Bulgaria and 4 more
- Volunteers
- 463 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?
The major objective of this proposal is to test the hypothesis that the addition of divalproex sodium to an atypical antipsychotic drug other than clozapine will significantly improve: a) cognition; and b) psychopathology…
- Trial name
- NCT00306475
- Testing
- Divalproex Sodium Extended-Release Tablets
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Healthy
A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
This is a 28-day, single-center, double-blind, placebo-controlled inpatient study of the administration of risperidone alone or in combination with mifepristone in healthy adult male volunteers to determine the average change in…
- Trial name
- NCT00698022
- Testing
- Risperidone, Mifepristone
- Where
- India
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Cancer, Severe Major Depression
Bridge: Proactive Psychiatry Consultation and Case Management for Patients With Cancer
The purpose of this research is to understand if it is helpful for patients with mental illness to be connected to a psychiatrist and case manager at the time of cancer diagnosis.
- Conditions
- Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder
- Trial name
- NCT03360695
- Testing
- Proactive Psychiatry Consultation (PPC), Enhanced Usual Care (EUC)
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Bipolar Disorder
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
The purpose of this study is to assess the efficacy of d-cycloserine (DCS) as an augmentation strategy in two psychotic patients with a triplication (4 copies) of the glycine decarboxylase (GLDC) gene.
- Trial name
- DCS (NCT02304432)
- Testing
- D-cycloserine
- Volunteers
- 2 people
- Sponsor
- Mclean Hospital